Search

Zentalis Pharmaceuticals Inc

Geschlossen

3.67 -0.81

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.58

Max

3.8

Schlüsselkennzahlen

By Trading Economics

Einkommen

-42M

-78M

EPS

-0.59

Angestellte

106

EBITDA

-42M

-77M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+138.65% upside

Dividenden

By Acuity

Nächstes Ergebnis

6. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

20M

351M

Vorheriger Eröffnungskurs

4.48

Vorheriger Schlusskurs

3.67

Zentalis Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Aug. 2026, 23:56 UTC

Correlated Moves

Hecla Mining Co shares are lower in after-market trading, pressured by declining silver prices and rising sovereign bond yields amid inflation concerns.

18. Aug. 2026, 23:56 UTC

Huntington Ingalls Industries shares are higher in after-market trading, reflecting strength above its 20-day moving average and near the upper end of its one-month range.

18. Aug. 2026, 23:56 UTC

News

Exelixis shares are lower in after-market hours following BMO's Market Perform rating. Broader market pressures from rising bond yields also weigh on the stock.

18. Aug. 2026, 23:56 UTC

American Water Works shares are higher in after-market trading, despite rising sovereign bond yields impacting investor sentiment across equities.

18. Aug. 2026, 23:56 UTC

Coursera Inc shares are higher in after-market trading, despite no specific news driving the movement. Broader market conditions reflect rising sovereign bond yields.

18. Aug. 2026, 23:56 UTC

Correlated Moves
Social Media

The iShares Core U.S. Aggregate Bond ETF rose slightly in after-market trading, reflecting recent fluctuations in the 10-year yield and broader market sentiment.

18. Aug. 2026, 23:56 UTC

Steel Dynamics Inc shares are trading lower in after-market hours, remaining below the 20-day moving average amid ongoing market weakness. No specific news was identified.

18. Aug. 2026, 23:56 UTC

Chipotle Mexican Grill Inc shares are higher in after-market trading, reflecting a modest increase since Tuesday's close amid rising sovereign bond yields.

18. Aug. 2026, 23:56 UTC

Array Technologies Inc shares are higher in after-market trading, reflecting a modest gain since Tuesday's close. The stock remains below its 20-day moving average.

18. Aug. 2026, 23:56 UTC

News

Carvana Co's shares are higher in after-market trading amid concerns over major shareholder Mark Walter's federal investigation and potential stake sale valued at $2 billion.

18. Aug. 2026, 23:56 UTC

Correlated Moves

Vicor Corp shares are lower in after-hours trading amid broader market volatility and concerns over rising bond yields and geopolitical tensions.

18. Aug. 2026, 23:56 UTC

VF Corp shares are higher in after-market trading following a recovery from an earlier decline. The price remains below its 20-day moving average.

18. Aug. 2026, 23:56 UTC

Fastenal Co shares are higher in after-market trading, maintaining performance above the 20-day moving average despite concerns over rising sovereign bond yields.

18. Aug. 2026, 23:56 UTC

Paccar Inc shares rose in after-market trading, despite no specific news. The stock remains below its 20-day moving average amid broader market pressures.

18. Aug. 2026, 23:56 UTC

Correlated Moves

Morgan Stanley shares are lower in after-market trading amid unusual volatility and rising bond yields, which are pressuring equities and growth prospects.

18. Aug. 2026, 23:56 UTC

Social Media

Johnson & Johnson returns the C-CAR039 program to AbelZeta, while discussions about a potential acquisition of Legend Biotech continue. Shares are roughly flat in after-market trading.

18. Aug. 2026, 23:56 UTC

Correlated Moves

Campbell Soup Co shares are higher in after-market trading, advancing since Tuesday's close and positioning above the 20-day moving average.

18. Aug. 2026, 23:56 UTC

Upbound Group Inc shares are higher in after-market hours, recovering from three consecutive lower closes, though still below the 20-day moving average.

18. Aug. 2026, 23:56 UTC

CEVA Inc. shares gained in after-market trading, reaching a high above Tuesday's close, though they remain below their 20-day moving average.

18. Aug. 2026, 23:56 UTC

Coca-Cola Co's shares are higher in after-market trading, reflecting a modest increase since Tuesday's close. The stock remains above its 20-day moving average.

18. Aug. 2026, 23:52 UTC

News
Social Media

IONQ partners with CMC Microsystems to enhance cloud quantum computing access in Canada. Shares are lower in after-market hours following the announcement.

18. Aug. 2026, 23:51 UTC

Agilent Technologies Inc shares declined in after-market hours amid broader market concerns over rising bond yields and inflation linked to geopolitical tensions.

18. Aug. 2026, 23:51 UTC

Genpact Ltd shares are lower in after-market hours amid concerns over elevated bond yields and inflation, despite initial gains earlier in the session.

18. Aug. 2026, 23:51 UTC

Northrop Grumman shares are higher in after-market hours, remaining above their 20-day moving average and near the upper end of their one-month range.

18. Aug. 2026, 23:51 UTC

Correlated Moves

Lennox International Inc shares are higher in after-market trading, reflecting broader trends in correlated assets like Toll Brothers Inc amid rising bond yields.

18. Aug. 2026, 23:51 UTC

Correlated Moves

Pultegroup Inc shares are lower in after-market hours, following declines in the Russell 2000 Index and rising concerns over elevated bond yields.

18. Aug. 2026, 23:51 UTC

Correlated Moves

Ichor Holdings Ltd shares are lower in after-market hours, influenced by a decline in the Nasdaq 100 Index and rising bond yields.

18. Aug. 2026, 23:51 UTC

Monday.Com Ltd. shares declined after-market amid concerns over rising bond yields and inflation. The stock remains above its 20-day moving average.

18. Aug. 2026, 23:51 UTC

Cardinal Health Inc. shares are lower in after-market trading, maintaining declines amid broader market concerns over elevated bond yields and inflation linked to geopolitical tensions.

18. Aug. 2026, 23:51 UTC

Correlated Moves

Lam Research shares declined in after-market trading, influenced by rising bond yields and broader market trends, including a slight drop in the Nasdaq 100 Index.

Peer-Vergleich

Kursveränderung

Zentalis Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

138.65% Vorteil

12-Monats-Prognose

Durchschnitt 8.83 USD  138.65%

Hoch 11 USD

Tief 5 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Zentalis Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

5

Buy

1

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat